NASDAQ:RCKT Rocket Pharmaceuticals Q3 2024 Earnings Report $4.24 +0.17 (+4.18%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$4.14 -0.10 (-2.24%) As of 07/8/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Rocket Pharmaceuticals EPS ResultsActual EPS-$0.71Consensus EPS -$0.78Beat/MissBeat by +$0.07One Year Ago EPSN/ARocket Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARocket Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/7/2024TimeAfter Market ClosesConference Call DateWednesday, November 6, 2024Conference Call Time6:00PM ETUpcoming EarningsRocket Pharmaceuticals' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Rocket Pharmaceuticals Earnings HeadlinesRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Recommendation of "Hold" from AnalystsJuly 2, 2026 | americanbankingnews.comFinancial Survey: Rocket Pharmaceuticals (NASDAQ:RCKT) & Pharma Mar (OTCMKTS:PHMMF)June 28, 2026 | americanbankingnews.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. | Altimetry (Ad)Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?June 25, 2026 | insidermonkey.comRocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 MillionJune 12, 2026 | businesswire.comRocket Pharmaceuticals, Inc. (RCKT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comSee More Rocket Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rocket Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rocket Pharmaceuticals and other key companies, straight to your email. Email Address About Rocket PharmaceuticalsRocket Pharmaceuticals (NASDAQ:RCKT) is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms. The company’s pipeline comprises multiple product candidates in various stages of development. Lead programs such as RP-L102 for Fanconi anemia and RP-L301 for leukocyte adhesion deficiency type I have advanced into clinical trials, where Rocket is evaluating safety and preliminary efficacy. Preclinical efforts include gene therapy candidates for Danon disease and other lysosomal storage disorders. Rocket leverages in-house manufacturing capabilities alongside strategic partnerships to support its clinical and potential commercial supply needs. Founded in 2015 as a spin-out from academic research institutions, Rocket Pharmaceuticals established its headquarters in New York City. Since inception, the company has expanded its research and development infrastructure to include state-of-the-art manufacturing and clinical trial support facilities. Its management team draws upon expertise in gene therapy development, regulatory strategy and rare disease commercialization to guide programs from laboratory to the clinic. Rocket Pharmaceuticals serves patient populations primarily in the United States and collaborates with international academic and clinical centers to advance global trial enrollment. The company’s efforts are underpinned by partnerships with nonprofit organizations and academic research groups dedicated to rare disease advocacy, reflecting a commitment to bringing transformative therapies to underserved communities worldwide.View Rocket Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Exxon Could Be the Market's Next Big Comeback StockWhy Penguin Solutions May Be the Smartest AI Infrastructure StockMeta Platforms’ Cloud Push: Growth Opportunity Versus AI ConcernsThese 3 Cash-Flow Stocks Give Investors More Than Just Growth PotentialDrone Stocks Are Down, But Defense Backlogs Tell a Different StoryGE Vernova’s Power Surge Turns the Grid Into an AI Trade2 Short Squeezes for Summer Speculation: What the Bears Are Getting Wrong Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
